Roberta Ondei

Mrs. Roberta Ondei

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAnanda Pulini Matarazzo
Ananda Pulini Matarazzo
CRCarlos A. Rios
Carlos A. Rios
GGGabriela Geronimo
Gabriela Geronimo
RORoberta Ondei
Roberta Ondei
Eneida De PaulaEneida De Paula
Eneida De Paula
MBMarcia Cristina Breiktreitz
Marcia Cristina Breiktreitz
Nanostructured lipid carriers (NLCs) are typically composed of liquid lipids, solid lipids, and surfactants, enabling the encapsulation of lipophilic drugs. Butamben is a Class II anesthetic drug, according to the Biopharmaceutical Classification System (BCS); it has a log P of 2.87 and is considered a ‘brick dust’ (poorly water-soluble and poorly lipid-soluble) drug. This characteristic poses a challenge for the development of NLCs, as they are not soluble in the liquid lipid present in the NLC core. In a previous study, we developed an NLC core consisting of a solid lipid (CrodamolTM CP), a lipophilic liquid with medium polarity (SRTM Lauryl lactate), and a hydrophilic excipient (SRTM DMI) that allowed the solubilization of ‘brick dust’ types of drugs, including butamben. In this study, starting from the NLC core formulation previously developed we carried out an optimization of the surfactant system and evaluated their performance in aqueous medium. Three different surfactants (CrodasolTM HS HP, SynperonicTM PE/F68, and CroduretTM 40) were studied and, for each of them, a 23 factorial design was stablished, with total lipids, % surfactant, and sonication time (min) as the input variables and particle size (nm), polydispersity index (PDI), and zeta potential (mV) as the response variables. Stable NLCs were obtained using CrodasolTM HS HP and SynperonicTM PE/F68 as surfactants. Through a comparison between NLCs developed with and without SRTM DMI, it was observed that besides helping the solubilization of butamben in the NLC core, this excipient helped in stabilizing the system and decreasing particle size. NLCs containing CrodasolTM HS HP and SynperonicTM PE/F68 presented particle size values in the nanometric scale, PDI values lower than 0.3, and zeta potentials above |10|mV. Concerning NLCs’ stability, SBTB-NLC with SynperonicTM PE/F68 and butamben demonstrated stability over a 3-month period in aqueous medium. The remaining NLCs showed phase separation or precipitation during the 3-month analysis. Nevertheless, these formulations could be freeze-dried after preparation, which would avoid precipitation in an aqueous medium.

8 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CRCarlos Alberto Rios
Carlos Alberto Rios
RORoberta Ondei
Roberta Ondei
MBMarcia Cristina Breiktreitz
Marcia Cristina Breiktreitz
The objective of this study was to develop a versatile lipid core for the ‘brick-dust type of drugs’ (poorly water-soluble and poorly lipid-soluble drugs). In the first step, excipients of different polarities were classified according to their behavior in aqueous solutions. Subsequently, binary mixtures were prepared with cetyl palmitate (Crodamol™ CP pharma, Campinas, São Paulo, Brazil) as the solid lipid, and its miscibility with other excipients was evaluated using Raman mapping and classical least squares (CLS). Based on the results, the excipients Crodamol™ CP pharma (hydrophobic), Super Refined™ DMI (dimethyl isosorbide; hydrophilic, Mill Hall, PA, USA), and Super Refined™ Lauryl Lactate (lauryl lactate, medium polarity, Mill Hall, PA, USA) were chosen to compose the lipid core. The ideal proportion of these excipients was determined using a mixture design and the standard deviation (STD) of image histograms as the response variables. After statistical evaluation of the DoE results, the final composition was determined, and drugs with different logP (0 to 10) and physicochemical characteristics were evaluated in the optimized mixture. The drugs butamben (Sigma-Aldrich Co., Spruce Street, St. Louis, MO, USA), tacrolimus (NutriFarm, São Paulo, Brazil), atorvastatin calcium, and resveratrol (Botica da Terra, Campinas, Brazil) presented a homogeneous distribution in the optimized lipid core, indicating that this is a promising system to be used in nanostructured lipid carrier (NLC) formulations of such types of drugs.

31 January 2024 in Nanomedicine
Verified
Journal Article
Closed access
GBGabriel Borges
Gabriel Borges
TSThais Tunes Santos
Thais Tunes Santos
CPCristiane Monteiro Pinto
Cristiane Monteiro Pinto
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
VBVerônica Freitas Blanco
Verônica Freitas Blanco
GGGisele Assis Castro Goulart
Gisele Assis Castro Goulart
Aim: To develop nanoemulsions (NEs) loading amphotericin B (AmB) and to evaluate the influence of different excipients on the stability and the supramolecular organization, retention and toxicity o... Graphical abstract Disteaoryl phosphatidylglycerol and dioleoyl phosphatidylglycerol form a hydrophobic ion pair with amphotericin B in nanoemulsions, enhancing drug retention after dispersion and ...

8 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
CRCarlos Alberto Rios
Carlos Alberto Rios
RORoberta Ondei
Roberta Ondei
MBMarcia Cristina Breiktreitz
Marcia Cristina Breiktreitz
In the study, a lipid mixture was developed and optimized using a broad range of excipients of different po-larities. Initially, the excipients were classified according to their behavior in water. Then binary mixtures were prepared using cetyl palmitate (Crodamol™ CP pharma) as the solid lipid. The miscibility between the excipients was evaluated using Raman chemical images obtained by classical least squares (CLS). Based on the results, the excipients Crodamol™ CP pharma (cetyl palmitate, hydrophobic), Super Refined™ DMI (di-methyl isosorbide; hydrophilic) and Super Refined™ Lauryl Lactate (medium polarity) were chosen to com-pose the lipid core. The ideal proportion of these excipients was determined using a Mixture Design and the standard deviation of image histograms as responses. The main goal was to develop a versatile lipid core for ‘brick-dust type of drugs’. After statistical evaluation of the DOE results, the final composition was deter-mined and drugs with different logP (0 to 10) and physiochemical characteristics were evaluated in the opti-mized mixture. The drugs butamben, tacrolimus, atorvastatin calcium and resveratrol presented a homoge-neous distribution in the optimized lipid core, indicating that the core has indeed the capability to be used in NLC formulations of such type of drugs.

6 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAnanda Pulini Matarazzo
Ananda Pulini Matarazzo
CRCarlos Alberto Rios
Carlos Alberto Rios
GGGabriela Geronimo
Gabriela Geronimo
RORoberta Ondei
Roberta Ondei
Eneida De PaulaEneida De Paula
Eneida De Paula
MBMarcia Cristina Breiktreitz
Marcia Cristina Breiktreitz
Nanostructured lipid carriers (NLC) are typically composed of liquid lipids, solid lipids, and surfactants, enabling the encapsulation of lipophilic drugs. Butamben is a Class II anesthetic drug according to the Biopharmaceutical Classification System (BCS), it has a log P 2.87 and is considered a 'brick dust' (poorly water-soluble and poorly lipid-soluble) drug. This characteristic poses a challenge for the development of NLCs, as they are not soluble in the liquid lipid present in the NLC core. In a previous study [1] we have developed a NLC core consisting of solid lipid (CrodamolTM CP), liquid lipid of medium polarity (SRTM Lauryl lactate), and a hydrophilic excipient (SRTM DMI) that allowed the solubilization of 'brick dust' type of drugs including butamben. In this study, starting from the NLC core formulation previously developed we carried out the optimization of the surfactant system and evaluated their performance in aqueous medium. Three different surfactants (CrodasolTM HS HP, SynperonicTM PE/F68, and CroduretTM 40) were studied and, for each of them, a 2³ factorial design was stablished, with total lipids, % surfactant, and sonication time (min) as the input variables and particle size (nm), polydispersity index (PDI) and zeta potential (mV) as the response variables. Stable NLCs were obtained using CrodasolTM HS HP and SynperonicTM PE/F68 as surfactants. Through a comparison between NLCs developed with and without SRTM DMI, it was observed that besides helping the solubilization of butamben in the NLC core, this excipient helped stabilizing the system and decreasing particle size NLCs containing CrodasolTM HS HP and SynperonicTM PE/F68 presented particle size values in the nanometric scale, PDI lower than 0.3 and zeta potential above |10|mV. Concerning NLCs stability, SBTB-NLC with SynperonicTM PE/F68 and butamben demonstrated stability over a 3-month period in aqueous medium. The remaining NLCs showed phase separation or precipitation during the 3-month analysis. Nevertheless, these formulations could be freeze-dried after preparation, which would avoid precipitation in aqueous medium.